Targeting the cholinergic anti‐inflammatory pathway for type 2 diabetes prevention: A retrospective cohort study
Galantamine use was associated with a lower risk of T2DM in early-onset AD patients, potentially due to enhanced anti-inflammatory effects through both AChE inhibition and direct α7nAChR agonism. Memantine also demonstrated a protective effect. These findings suggest potential new applications for existing AD medications in T2DM prevention, particularly in early-onset AD patients. Further research, including randomized controlled trials with diverse populations, is needed to confirm these results and the underlying mechanisms.
Authors
- Tammy H. Cummings (ORCID: https://orcid.org/0000-0001-7978-7157)
- S. Scott Sutton
- Joseph Magagnoli (ORCID: https://orcid.org/0000-0002-8568-0097)
- James W. Hardin (ORCID: https://orcid.org/0000-0003-0506-5500)
- Jayakrishna Ambati (ORCID: https://orcid.org/0000-0003-1622-6365)
Institutions
- University of South Carolina (US)
- Columbia VA Health Care System (US)
- Dorn Research Institute (US)
- University of Virginia (US)
Publication Details
- Journal
- Diabetes Obesity and Metabolism
- Published
- 2024-11-11
- DOI
- https://doi.org/10.1111/dom.16060
- Citations
- 3
- Primary Topic
- Vagus Nerve Stimulation Research
- Type
- article
- Field-Weighted Citation Impact
- 0.74
Funders
- U.S. Department of Veterans Affairs
- National Institutes of Health